GlassScriptPhysician profile
Blair Greenwood
NPI 1932137148
$7,455.12
in general payments reported to CMS, 2019-2025
49 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $815 · 2021: $1,062 · 2022: $810 · 2023: $1,099 · 2024: $1,397 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,191.50 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $901.48 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $896.65 | 2019-2025 | |
| Amgen INC. | $489.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $424.78 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $296.58 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $252.01 | 2019-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.98 | 2025 | Caplyta |
| Upsher-Smith Laboratories LLC | $186.54 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $179.93 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $172.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $170.55 | 2024-2025 | Vyepti, Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.83 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $159.25 | 2019-2023 | Belsomra, Steglatro |
| Shield Therapeutics INC | $135.11 | 2023-2024 | Accrufer |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blair Greenwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.